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Methylation of cytosine at CpG dinucleotides is a common feature of many higher eukaryotic genomes. A
major biological consequence of DNA methylation is gene silencing. Increasing evidence indicates that re-
cruitment of histone deacetylase complexes by methyl-CpG-binding proteins is a major mechanism of meth-
ylated DNA silencing. We have previously reported that the MeCP1 protein complex represses transcription
through preferential binding, remodeling, and deacetylation of methylated nucleosomes. To understand the
molecular mechanism of the functioning of the MeCP1 complex, the individual components of the MeCP1
complex need to be characterized. In this paper, we report the identification and functional characterization
of the p66 and p68 components of the MeCP1 complex. We provide evidence that the two components are
different forms of the same zinc finger-containing protein. Analysis of the p66 homologs from different
organisms revealed two highly conserved regions, CR1 and CR2. While CR1 is involved in the association of
p66 with other MeCP1 components, CR2 plays an important role in targeting p66 and MBD3 to specific loci.
Thus, our study not only completes the identification of the MeCP1 components but also reveals the potential
function of p66 in MeCP1 complex targeting. The identification and characterization of all the MeCP1
components set the stage for reconstitution of the MeCP1 complex.
Dynamic changes in chromatin structure play important
roles in DNA-templated processes, such as transcription, rep-
lication, recombination, and repair (11, 17). Thus far, at least
two types of enzymatic activities have been identified that are
capable of altering chromatin structure to allow protein factors
access to nucleosomal DNA. One involves multiprotein com-
plexes that utilize energy derived from ATP hydrolysis to
“remodel” nucleosomes (16, 17); the other involves covalent
modification, in particular acetylation/deacetylation, of core
histone tails (13). The purification and functional character-
ization of the nucleosome remodeling and histone deacetylase
(HDAC) complex, NuRD/Mi-2 complex, suggest that the two
chromatin-modifying enzymatic activities could be coupled
(15, 19, 22, 24).
NuRD/Mi-2 complex is a multiprotein complex that pos-
sesses both nucleosome remodeling and histone deacetylase
activities (15, 19, 22, 24). This complex has been purified from
both HeLa cells and Xenopus laevis eggs (18, 24). When the
complex was purified from HeLa cells, seven major polypep-
tides were identified (24). In addition to the four-subunit his-
tone deacetylase core, HDAC1/2 and RbAp46/p48, which is
also present in the Sin3 histone deacetylase complex (23, 26),
NuRD contains at least three more subunits: Mi2, MTA2, and
MBD3 (24, 25). Mi2 is a SWI2/SNF2 type helicase/ATPase
domain-containing protein that was first identified as a der-
matomyositis-specific autoantigen (12) and has recently been
demonstrated to be responsible for the remodeling activity of
the NuRD complex (1, 20). MTA2 is a novel protein that is
highly similar (65% identical) to the candidate metastasis-
associated protein MTA1 (14, 25). Biochemical characteriza-
tion of MTA2 indicates that it plays an important role in
modulating the histone deacetylase activity of the NuRD com-
plex (25). MBD3 is a methyl-CpG-binding domain-containing
protein, similar to MBD2 (4). However, the function of MBD3
in the NuRD complex is not known (25). When the complex
was purified from Xenopus egg extracts, it was composed of six
subunits: the ATPase xMi2, the MTA1-like protein (xMTA2),
the histone deacetylase xRpd3, the histone binding protein
xRbAp48, the methyl-CpG-binding domain-containing protein
xMBD3, and a zinc finger protein, p66 (18). Thus, most of the
NuRD/Mi-2 components are conserved between humans and
Xenopus.
The identification of a methyl-CpG-binding domain-con-
taining protein MBD3 in the NuRD/Mi2 complex suggests that
this complex may potentially be recruited to methylated DNA
for transcriptional silencing. A gel-mobility-shift assay revealed
that the highly purified seven-component NuRD complex does
not show affinity binding to methylated DNA (25). However,
the NuRD complex can be targeted to methylated DNA in
vitro through an interaction with the methyl-CpG-binding pro-
tein MBD2 (25). This in vitro interaction was substantiated by
the recent demonstration that the NuRD complex is able to
associate with MBD2 in vivo to form the MeCP1 complex (3).
The MeCP1 complex was initially described as a methyl-CpG-
specific binding activity (7) and has been shown to include
MBD2 and the histone deacetylase core, HDAC1/2 and
RbAp46/p48 (9). Using a methyl-CpG-specific-binding assay
and Western blot analysis, we have recently purified and de-
fined the molecular composition of the MeCP1 complex to
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include MBD2, all seven NuRD components, and two novel
polypeptides of 66 and 68 kDa (3). Importantly, the MeCP1
complex is able to repress transcription through preferential
binding, remodeling, and deacetylation of methylated nucleo-
somes (3).
To analyze the MeCP1 complex further, we have now iden-
tified and characterized the two novel components of the
MeCP1 complex, p66 and p68. We found that the two polypep-
tides represent different modified forms of the same protein
that is conserved from Caenorhabditis elegans to humans. The
protein contains two highly conserved regions, CR1 and CR2.
We provide evidence that CR1 is involved in the association of
p66/p68 with the MeCP1 complex, while CR2 is required for
the localization of p66/p68 and MBD3 to specific loci. Our data
support a potential function of p66/p68 in MeCP1 complex
targeting.
MATERIALS AND METHODS
p66/p68 identification, cloning, and DNA constructs. The procedure for the
purification of the MeCP1 complex has been described previously (3). The
purified MeCP1 complex was separated by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis (SDS-PAGE) and stained with Coomassie blue. The p66
and p68 bands were excised and subjected to in-gel tryptic digestion and mass
spectrometric analysis as previously described (2). Mass spectrometric analysis of
the protein bands corresponding to p66 and p68 revealed that they both have
peptide masses that match a cDNA clone, KIAA1150, in the HUGE database
(www.kazusa.or.jp/huge). 5 rapid amplification of cDNA ends (5 RACE)
(Gibco BRL) extended the KIAA1150 cDNA 297 bp at the 5 end. The longest
cDNA for p66 contains 5,348 bp encoding 593 amino acids. All the p66 con-
structs were generated by PCR using the human p66 cDNA as a template. All
clones were verified by DNA sequencing. The various deletions of Gal4-DNA
binding domain-p66 constructs used in Fig. 4C were made by PCR amplification
of the human p66 cDNA and cloning into the EcoRI and XbaI sites of vector
pSG424. The various p66 fragments were released and cloned into pFlag-CMV2
and pBluescript to generate the Flag-tagged constructs used in Fig. 3B and Fig.
5B, and for in vitro translation used in Fig. 2B. The pEGFP-p66 constructs used
in Fig. 5A were generated by the same method. The mouse p66 sequence was
derived from assembly of overlapping mouse expressed sequence tag (EST)
clones. All the constructs for glutathione S-transferase (GST) fusion proteins
used in Fig. 2A and GFP-MBD3 used in Fig. 5 have been described previously
(4, 9, 25, 26).
GST pulldown assay. Two micrograms of GST or GST fusion proteins was
bound to 10 l of glutathione-immobilized agarose beads (Sigma) and incubated
with an equal amount of in vitro-translated full-length p66 or deletion mutant
p66 in 300 l of buffer B (50 mM Tris-HCl [pH 7.9], 0.5 mM EDTA, 1 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 10% glycerol) containing
150 mM KCl and 0.05% NP-40. After incubation at 4°C for 4 to 8 h, the beads
were washed three times with buffer B containing 300 mM KCl and 0.05% NP-40
before being resolved by SDS-PAGE. When dry, the gels were exposed to X-ray
film. In vitro translation was performed using the rabbit reticulocyte lysate kit
according to the manufacturer’s instructions (Promega).
Luciferase assay. About 1.5  105 293T cells were seeded in each well of a
12-well plate 1 day before transfection. A total of 300 ng of plasmid DNA,
including 50 ng of pCH110 (Pharmacia) encoding -galactosidase, was used for
each transfection using the Qiagen Effectene Transfection Reagent. Twenty-four
hours after transfection, cells were harvested, and luciferase and -galactosidase
activities were measured by using the luciferase and -galactosidase assay sys-
tems (Promega). Transfection efficiency was normalized by using the -galacto-
sidase assay. For Tricostantin A (TSA) treatment, TSA was added to the culture
medium (final concentration, 100 ng/ml) 24 h posttransfection, and cells were
harvested after another 24 h of incubation.
Immunoprecipitation. Twenty-four hours after transfection, cells were har-
vested and washed with ice-cold phosphate-buffered saline (PBS) before being
lysed with lysis buffer (50 mM Tris, 150 mM NaCl, 0.1% NP-40, 50 mM NaF, 1
mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 g of aprotinin/ml, 0.5
g of leupeptin/ml, and 0.7 g of pepstatin/ml). After incubation for 30 min at
4°C, the cell debris was removed by centrifugation at 14,000 rpm for 5 min in an
Eppendorf centrifuge (Brinkmann Instruments, Inc.). About 1 mg of protein
extracts was incubated with 20 l of Flag-M2 agarose beads (Sigma) at 4°C for
4 h. After three washes with lysis buffer, the immunoprecipitated proteins were
analyzed by Western blotting.
Immunofluorescent staining. Twenty-four hours before transfection with the
Qiagen Effectene Transfection Reagent, about 105 NIH 3T3 cells were seeded in
each well of a 12-well plate. Twenty-four hours after transfection, cells were
washed twice with PBS and then fixed in 3% paraformaldehyde (in PBS) for 10
min at room temperature. After a wash with PBS, the cells were incubated with
0.2% Triton X-100 (in PBS) for 5 min at 4°C. Then the cells were blocked with
0.5% bovine serum albumin (in PBS) for 30 min and stained with anti-Flag M2
antibody (IBI; 1:1,000) for 1 h at room temperature. After three washes with
PBS, the cells were first incubated with rhodamine-conjugated goat anti-mouse
immunoglobulin G (IgG) (Jackson ImmunoResearch Laboratories) diluted 1:50
with 0.5% bovine serum albumin in PBS for 30 min and then stained with 1 g
of 4,6-diamidino-2-phenylindole (DAPI) (Sigma)/ml for 10 s. The cells were
then washed three times with PBS, mounted with DAKO fluorescent mounting
medium, and visualized by a Zeiss immunofluorescence microscope.
RESULTS
p66 and p68 are different forms of a novel zinc finger pro-
tein. Using a methyl-CpG-specific-binding assay and Western
blot analysis, we previously purified the MeCP1 complex (3).
The complex contains 10 polypeptides, including MBD2, the 7
known NuRD components, and 2 unidentified polypeptides of
66 and 68 kDa (Fig. 1A). To identify the two proteins, the
purified MeCP1 complex was resolved by SDS-PAGE. After
Coomassie staining, the protein bands corresponding to p66
and p68 were excised and subjected to in-gel tryptic digestion.
The resulting peptides were analyzed by mass spectrometry.
This analysis revealed that p66 and p68 have identical mass
spectra, which mostly match that of a conceptual tryptic diges-
tion of a partial cDNA clone, KIAA1150 (GenBank accession
number AB032976). Therefore, it is likely that p66 and p68
represent the same protein and that p68 is the modified form
(see below). For simplicity, we refer to the protein as p66.
Because KIAA1150 is a partial cDNA clone, we performed
5 RACE to isolate the full-length p66 cDNA. Sequencing of
several clones derived from 5 RACE resulted in extension of
the KIAA1150 clone by 297 bp. The combination of
KIAA1150 and the 5 extension resulted in a cDNA of 5,348 bp
encoding an open reading frame of 593 amino acids (Fig. 1B).
Mass spectrometric analysis identified four peptides that
match the conceptual translation of the 5 RACE product (Fig.
1B), suggesting that KIAA1150 and the RACE product encode
different regions of p66. In addition, we also verified the in-
tegrity of the cDNA by reverse transcription-PCR (data not
shown). Several lines of evidence indicate that the deduced 593
amino acids represent full-length p66. First, the calculated
molecular mass, 65.26 kDa, is almost identical to the estimated
apparent molecular mass of 66 kDa (data not shown). Second,
all the peptides of p66 and p68 that were identified by mass
spectrometry analysis (18 peptides for each) are included
within the 593 amino acids (Fig. 1B). Third, transfection of a
mammalian expression vector encoding p66 into 293T cells
generated a doublet comigrating with the native p66/p68 (data
not shown). Fourth, the first methionine conforms to the
Kozak initiator sequence (6).
Analysis of the entire coding sequence of p66 revealed a
GATA-type zinc finger domain (Fig. 1B). A search of the
GenBank databases with human p66 identified homologs in
the mouse, Xenopus, Drosophila melanogaster, and C. elegans
(Fig. 1C) which are 98.3, 46.4, 36.0, and 25.3% identical to
human p66, respectively. Interestingly, the p66 homolog in
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Xenopus had been previously identified as a component of the
Xenopus Mi-2 complex (18). However, the reported Xenopus
p66 contains only 420 amino acids, which is significantly
shorter than its human, mouse, fly, or worm homologs (Fig.
1C). Interestingly, a conceptual translation of the reported
Xenopus p66 cDNA upstream of the initiation methionine with
a frame shift extends the protein an additional 120 amino acids
with significant homology to the N-terminal amino acid se-
quence of human p66 (data not shown). A search of an EST
database identified a Xenopus EST clone (BG364338) that
contains such a frame shift. Therefore, it is possible that the
discrepancy between the Xenopus p66 and those from other
organisms lay in a sequencing error. Sequence comparison of
the p66 homologs from different organisms identified two
highly conserved regions, including a region with a GATA-type
zinc finger (Fig. 1C). It is interesting that, as with other
MeCP1-specific components (Mi2, MTA2, MBD2, and
MBD3), an apparent homolog of p66 was not found in Sac-
charomyces cerevisiae, suggesting that the MeCP1 complex is
likely involved in multicellular processes.
To confirm that the cDNA we cloned indeed encodes the
p66/p68 polypeptides present in the MeCP1 complex, a pep-
tide corresponding to amino acids 176 to 191 of p66 was used
to generate antibodies. Antibodies against this peptide specif-
ically recognized the 66- and 68-kDa proteins present in the
purified MeCP1 complex, as well as those present in the crude
0.6 M P11 fraction of the HeLa nuclear extracts (Fig. 1D).
Therefore, we conclude that the p66 protein identified is a
component of the MeCP1 complex. In agreement with our
conclusion, a recent study demonstrated copurification of p66
with a NuRD-like protein complex (5).
Conserved region 1 (CR1) of p66 is required for its associ-
ation with the MeCP1 complex. To gain insight into the func-
tion of p66 in the MeCP1 complex, we analyzed the ability of
p66 to interact with each of the MeCP1 components. Since our
efforts to express full-length p66 in a bacterial expression sys-
tem failed, we expressed p66 in vitro using the rabbit reticulo-
cyte lysate system and performed GST pulldown assays. Figure
2A demonstrates that p66 interacted with MBD3, as well as
with MBD2 and RbAp46/p48, in this assay. However, the p66–
MBD2 and p66–RbAp46/p48 interactions are weaker than that
between p66 and MBD3. These interactions are specific, as
evidenced by the fact that GST, HDAC1/2, and MTA2 failed
to interact with p66 under the same conditions. The differences
between the p66–MBD3 and p66–MBD2 interactions should
be noted. Although MBD2 and MBD3 are related proteins,
they have two major differences. While MBD2 has an N-ter-
minal extension, MBD3 contains a glutamic acid stretch at its
C terminus. Whether these differences account for their dif-
ferent affinities to p66 remains to be determined.
To characterize the p66/MBD3 interaction further, different
deletion constructs of p66 were generated and were used to
synthesize p66 mutant proteins for GST pulldown assays. The
results shown in Fig. 2B indicated that interaction between
MBD3 and p66 requires the presence of the CR1 region (com-
pare lanes 6 and 9). Thus, we conclude that CR1 of p66 plays
an important role in the p66–MBD3 association in vitro.
Having established the role of CR1 in p66–MBD3 associa-
tion in vitro, we sought to determine whether a similar role for
CR1 can be demonstrated in vivo. Therefore, N-terminal Flag-
tagged full-length p66, as well as several p66 deletion mutants,
was expressed in 293T cells. Protein extracts derived from the
transfected cells were used in immunoprecipitation experi-
ments using antibodies against Flag. The immunoprecipitates
were divided into two parts and analyzed by Western blotting
using antibodies against components of the MeCP1 complex
(Fig. 3A) or Flag (Fig. 3B). The results shown in Fig. 3A
indicate that while the MeCP1 components efficiently coim-
munoprecipitated with Flag-p66 (Fig. 3A, lane 8), they failed
to coimmunoprecipitate with Flag-tagged p66 mutants lacking
CR1 (Fig. 3A, lanes 2 and 7). In contrast, all the Flag-tagged
p66 mutants containing CR1 successfully coimmunoprecipi-
tated with components of the MeCP1 complex (Fig. 3A, lanes
3 to 6). Since similar amounts of Flag-p66(1–165) and Flag-
p66(1–190) (Fig. 3B, lanes 2 and 3) or Flag-p66(190–593) and
Flag-p66 (Fig. 3B, lanes 7 and 8) were present in the immu-
noprecipitates, the most reasonable explanation for the above
results is that CR1 of p66 is required for its association with
other components of the MeCP1 complex in vivo.
As discussed above, mass spectrometry studies suggest that
p68 is a modified form of p66. Consistent with this conclusion,
we found that all the Flag-tagged constructs that include the
N-terminal 165 amino acids generated a doublet recognized by
Flag antibodies (Fig. 3B, lanes 2 to 5). However, transfection
of a construct encoding Flag-p66(1–110) to 293T cells gener-
ated only a single protein band recognized by the anti-Flag
antibody (data not shown). Collectively, these data suggest that
the potential modification is likely to occur between amino
acids 110 and 165. Inspection of the amino acid sequence
between positions 110 and 165 identified a serine-rich region,
raising the possibility that p66 might be modified by phosphor-
ylation. However, phosphatase treatment of p66 has no effect
on the modification (data not shown). The nature and func-
tional significance of the modification are currently under in-
vestigation.
FIG. 1. p66 is a component of the human MeCP1 complex. (A) Silver staining of the purified MeCP1 complex. The identities of the
polypeptides are indicated. p68 is a modified form of p66. (B) Amino acid sequence of human p66. The peptides that match the masses obtained
from mass-spectrometric analysis are shown in red. Amino acid sequences derived from 5 RACE are boxed. (C) Alignment of human p66 with
its homologs from other organisms. Sequences used in the alignment include p66 from the human (AF411836), mouse (AF411837), Xenopus
(AF171099), Drosophila (AE003547), and C. elegans (T19482). Alignment was performed using the MultAlin program (www.toulouse.inra.fr/
multalin.html). Red and green represent 100% and more than 50% identity, respectively. The two highly conserved regions, CR1 and CR2, are
marked by rectangles. Arrowheads indicate the zinc finger. The peptide used for antibody production is underlined. Symbols: !, I or V; $, L or M;
%, F or Y; #, N, D, Q, E, B, or Z. (D) Western blot analysis using affinity-purified p66 antibodies. Samples used are crude nuclear extracts (0.6
M KCl elution from a phosphocellulose P11 column) and purified MeCP1 complex. Note that p66 can migrate as a doublet or triplet depending
on gel conditions.
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FIG. 2. CR1 is required for p66–MBD3 interaction in vitro. (A) p66 interacts with multiple components of the MeCP1 complex. In vitro-
translated p66 protein was subjected to GST pulldown assays using the purified GST fusion proteins given above the gel. After electrophoresis,
the gel was subjected to Coomassie blue staining (lower panel) and autoradiography (top panel). (B) CR1 is required for p66–MBD3 interaction.
Shown at the top are diagrams of full-length p66 and p66 deletion mutants used in the GST pulldown assays. Plus and minus signs represent
interaction and no interaction, respectively. Input lanes represent 10% of the total proteins used in the GST pulldown. Lanes 3, 6, 9, 12, and 15
show amounts of full-length p66 or p66 deletion mutants pulled down by GST-MBD3.
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Transcriptional repression by p66 requires CR1. The above
data establish that p66 is a component of the MeCP1 complex
and that CR1 is required for its incorporation into the MeCP1
complex. Previously, we demonstrated that targeting the
MeCP1 complex to a reporter through MBD2 resulted in tran-
scriptional repression (3, 9). Since p66 is a component of the
MeCP1 complex, we speculated that targeting the MeCP1
complex to a reporter through p66 would also result in tran-
scriptional repression. Accordingly, a reporter containing five
Gal4-DNA binding sites upstream of the thymidine kinase
(TK) promoter was cotransfected into 293T cells with a mam-
malian expression vector encoding Gal4-p66. Figure 4A dem-
onstrates that targeting p66 to a promoter resulted in dose-
dependent transcriptional repression.
Given the association of p66 with histone deacetylases (Fig.
1A and 3A), we expect that histone deacetylase activity is at
least partially responsible for the repression activity of p66. To
test this prediction, the transcriptional activity of p66 was an-
alyzed in the presence and absence of a histone deacetylase
inhibitor, TSA. Figure 4B demonstrates that the transcrip-
tional repression activity of p66 is partially released in the
presence of TSA. Therefore, p66-mediated transcriptional re-
pression is at least partially dependent on histone deacetyla-
tion.
FIG. 3. CR1 is required in order for p66 to interact with other components of the MeCP1 complex in vivo. (A) Western blot analysis of different
MeCP1 components. Cell lysates of 293T cells transfected with full-length Flag-tagged p66 and various deletion constructs were immunoprecipi-
tated with an anti-Flag antibody. The immunoprecipitates were resolved by SDS-PAGE, transferred to nitrocellulose filters, and probed with the
antibodies given at the right of the gel. The deletion constructs are given above the gel. (B) The same samples used for panel A were probed with
an anti-Flag antibody to show that all the constructs are expressed and that the modification of p66 is within the N-terminal 165 amino acids. Dots
indicate the corresponding p66 proteins.
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FIG. 4. Transcription repression by p66 requires CR1. (A) p66 represses transcription when tethered to a promoter. A reporter containing five
Gal4 binding sites upstream of the TK promoter was cotransfected into 293T cells with a plasmid encoding Gal4-p66. The amount of DNA for
each plasmid used in transfection is indicated. Transcription activity was determined by measuring luciferase activity. Transfection efficiencies were
normalized using -galactosidase assays. Data are averages of two independent experiments. Error bars, variations between two independent
duplicated experiments. (B) The transcription repression activity of p66 is partially dependent on histone deacetylase activity. Data presented are
ratios of luciferase activity in the presence or absence of the histone deacetylase inhibitor TSA (100 ng/ml). Two reporters with different promoters
were analyzed. Error bars, variations between two independent duplicated experiments. (C) The repression activity of p66 depends on CR1. (Left)
Diagrams of the reporter and Gal4–p66 deletion constructs. (Right) Luciferase activities of the different p66 deletion mutants relative to that of
the Gal4-DNA binding domain (Gal4-DBD). Transfection efficiencies were normalized and data were averaged as described for panel A.
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To analyze the p66-mediated transcriptional repression fur-
ther, different regions of p66 were fused to the Gal4-DNA
binding domain and tested for their abilities to repress a re-
porter gene containing Gal4-binding sites. The results shown in
Fig. 4C indicate that p66-mediated transcriptional repression
requires the presence of CR1 (compare rows 4 and 5). How-
ever, CR1 by itself does not seem to be sufficient for mediating
efficient transcriptional repression. Efficient transcriptional re-
pression by p66 requires the presence of CR1 and an extension
5 to CR1 (Fig. 4C; compare rows 5 and 10). Since the tran-
scriptional repression activity of p66 correlates with its ability
to associate with the MeCP1 components (Fig. 3A), we con-
clude that the major mechanism of p66-mediated transcrip-
tional repression involves the assembly and recruitment of the
MeCP1 complex. Collectively, the above data suggest that CR1
is responsible for the incorporation of p66 into the MeCP1
complex.
The CR2 of p66 is involved in localization of p66 and MBD3
to specific loci. Having established the role of CR1, we turned
our attention to another highly conserved region, CR2. This
region contains a GATA-type zinc finger motif (C-X2-C-X17-
C-X2-C). Previous studies have demonstrated that this type of
zinc finger is involved in protein-protein or protein-DNA in-
teraction (8, 21). Since our protein-protein interaction studies
did not suggest that CR2 has a role in the association of p66
with other MeCP1 components (Fig. 2 and data not shown), we
decided to investigate the role of CR2 in directing the cellular
localization of p66. We reasoned that if this region is involved
in targeting the MeCP1 complex by either direct binding to
DNA or indirect association with a DNA-binding protein, de-
letion of this region should change the staining patterns of p66
and components of the MeCP1 complex. After unsuccessful
attempts to use the affinity purified p66 peptide antibody to
examine the endogenous p66 protein, we transfected Flag- or
green fluorescent protein (GFP)-tagged p66 constructs into
NIH 3T3 and HeLa cells. Fluorescent staining and immuno-
staining revealed that expression of both constructs resulted in
similar nuclear staining patterns in both cell lines (Fig. 5A,
panel a, and data not shown). Comparison with the DAPI
staining pattern of the same cell (Fig. 5A, panel d) indicated
that GFP-p66 does not exclusively colocalize with heterochro-
matin. Deletion of the extreme C-terminal sequence did not
change the speckled staining pattern of p66 (Fig. 5A; compare
panels a and b). However, deletion of CR2 dramatically
changed the nuclear staining pattern of GFP-p66 from speck-
led to diffuse in most transfected cells (Fig. 5A; compare pan-
els b and c). This result supports an important role of CR2 in
directing p66 to specific nuclear loci.
Having established a role of CR2 in directing p66 to specific
nuclear loci, we asked whether it also has a role in the local-
ization of the other MeCP1 components. Since our protein-
protein interaction studies indicated that p66 interacts with
MBD3 (Fig. 2), we asked whether p66 can direct MBD3 local-
ization. Consistent with the findings of previous studies (4),
GFP-MBD3 showed a diffuse nuclear localization pattern (Fig.
5B, panel a). However, cotransfection of Flag-p66 and GFP-
MBD3 changed the GFP-MBD3 localization pattern from dif-
fuse to speckled (Fig. 5B; compare panels a and c). Impor-
tantly, GFP-MBD3 and Flag-p66 completely colocalized (Fig.
5B, panel e). Thus, we conclude that p66 has a role in directing
MBD3 localization.
To determine whether CR2 of p66 is required for directing
MBD3 to specific nuclear loci, we compared the effects of two
p66 mutants with or without CR2 on GFP-MBD3 localization.
Like the wild-type Flag-p66, the CR2-containing mutant Flag-
p66(1–480) was capable of directing GFP-MBD3 to specific
nuclear loci (Fig. 5B; compare panels c through f and g through
j). However, the CR2 deletion mutant Flag-p66(1–340) lost its
ability to direct itself as well as GFP-MBD3 to specific nuclear
loci, resulting in a diffuse nuclear staining pattern (Fig. 5B,
panels k through m). Thus, collectively, these results support a
potential role of CR2 in targeting both p66 and MBD3 to
specific nuclear loci.
Previous studies indicated that GFP-MBD3 has a diffuse
nuclear staining pattern in cells when expressed at a low level
but accumulates in nuclear foci in cells when expressed at a
high level (4). To address the possibility that coexpression of
Flag-p66 simply increased the GFP-MBD3 level, resulting in
nuclear speckles, different amounts of GFP-MBD3 were trans-
fected with or without the presence of Flag-p66. Calculation of
the cell population with a speckled GFP-MBD3 pattern indi-
cated that increasing the GFP-MBD3 level only slightly in-
creased the speckled cell population (Fig. 5C). However, co-
expression of Flag-p66 dramatically increased the speckled cell
population (Fig. 5C). In addition, the different staining pat-
terns of the CR2-containing mutants and the CR2 deletion
mutants also argue against the possibility that our observation
is due to a dosage effect. It is worth noting that while the data
presented were obtained using NIH 3T3 cells, similar results
were also obtained using HeLa cells (data not shown). There-
fore, we conclude that CR2 of p66 plays an important role in
targeting p66 and MBD3 to specific nuclear loci.
DISCUSSION
The MeCP1 complex was originally described as a methyl-
CpG-binding activity (7). Although this activity was identified
more than 10 years ago, the molecular composition of the
complex has been elusive. It has recently been found that the
methyl-CpG-binding domain containing protein MBD2 is a
component of the MeCP1 complex, which also includes the
histone deacetylases HDAC1 and HDAC2 (9). In an effort to
define the molecular composition of the MeCP1 complex, we
purified the MeCP1 complex by monitoring MBD2 and its
methyl-CpG-binding activity (3). We found that the MeCP1
complex is composed of 10 polypeptides, including MBD2, all
the 7 NuRD components, and 2 novel proteins of 66 and 68
kDa (3). This complex is able to repress transcription of meth-
ylated DNA through preferential binding, remodeling, and
deacetylation of methylated nucleosomes (3). To further char-
acterize the MeCP1 complex, we have now identified and char-
acterized the p66 and p68 components. Thus, all 10 of the
MeCP1 components have been identified.
Mass spectrometry analysis of p66 and p68 indicates that p68
is a modified form of p66. Deletion studies indicate that the
modification resides within a serine-rich region between amino
acids 110 and 165. Preliminary studies indicate that the mod-
ification is not likely to be phosphorylation, since it is resistant
to phosphatase treatment. The molecular nature and function
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of this modification are currently under investigation. Proteins
with significant sequence homology to human p66 can be
found in diverse multicellular organisms including C. elegans,
Drosophila, Xenopus, and mice, indicating that the function of
p66 is evolutionarily conserved. Sequence analysis of the p66
homologs identified two highly conserved regions, CR1 and
CR2. Protein-protein interaction and deletion studies indicate
that CR1 is not only involved in MBD3–p66 interaction in vitro
(Fig. 2); it is also required for incorporation of p66 into the
MeCP1 complex in vivo (Fig. 3). Consistent with its role in
incorporation of p66 into the MeCP1 complex, CR1 is required
for the transcriptional repression activity of p66 (Fig. 4).
To determine the biochemical function of p66 in the MeCP1
complex, a baculovirus expressing p66 was generated. We
formed subcomplexes by coinfection of Sf9 cells with a p66-
expressing baculovirus and baculoviruses expressing other
components of the MeCP1 complex, followed by immunopre-
cipitation. Analysis of the histone deacetylase activities of the
different subcomplexes indicates that p66 has no effect on
histone deacetylase activity (data not shown). Since all of our
efforts to establish a role of p66 in modulating the known
biochemical properties of the MeCP1 complex had negative
results, we explored the possibility that p66 functions as a
targeting subunit. We found that deletion of CR2 changed the
nuclear localization pattern of p66 from speckled to diffuse
(Fig. 5A). Consistent with a potential role of p66 in targeting
the MeCP1 complex to specific loci, coexpression of p66
changed the GFP-MBD3 nuclear pattern from diffuse to
speckled (Fig. 5B). Importantly, the ability of p66 to direct
GFP-MBD3 to specific nuclear loci depends on CR2 (Fig. 5B).
Collectively, our data support a potential role of p66 in target-
ing the MeCP1 complex to specific nuclear loci.
The MBD2 component of the MeCP1 complex can bind
specifically to methylated DNA (3, 4, 9). It is possible that p66
might play an important role in determining which methylated
DNA MBD2 binds. A notable feature of CR2 is that it contains
a GATA-type zinc finger found in several GATA transcription
factors (8, 21). However, p66 is not likely to be capable of
binding to the GATA sequence, because several amino acids
known to be required for GATA sequence binding are not
conserved in the p66 zinc finger (10). It is possible that CR2
may recognize a DNA sequence similar to the GATA se-
quence. Alternatively, it is also possible that CR2 may be
involved in interaction with a DNA binding protein. Further
work is needed to understand how CR2 is involved in deter-
mining the localization of p66 as well as that of MBD3.
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